Enzo Biochem (NYSE:ENZ) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of Enzo Biochem (NYSE:ENZ) in a report issued on Friday. The firm issued a hold rating on the medical research company’s stock.

Enzo Biochem Stock Down 3.7 %

Enzo Biochem stock opened at $0.68 on Friday. The company has a 50 day moving average price of $0.94 and a 200 day moving average price of $1.06. Enzo Biochem has a 52 week low of $0.68 and a 52 week high of $1.44.

Enzo Biochem (NYSE:ENZ) last posted its earnings results on Monday, December 16th. The medical research company reported ($0.05) earnings per share (EPS) for the quarter. Enzo Biochem had a negative net margin of 81.73% and a negative return on equity of 11.84%.

Enzo Biochem Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, December 2nd. Investors of record on Friday, November 15th were paid a dividend of $0.10 per share. The ex-dividend date was Friday, November 15th. This represents a $0.40 annualized dividend and a yield of 58.81%.

Institutional Investors Weigh In On Enzo Biochem

Large investors have recently modified their holdings of the stock. XTX Topco Ltd grew its position in Enzo Biochem by 94.5% during the 2nd quarter. XTX Topco Ltd now owns 28,262 shares of the medical research company’s stock worth $31,000 after acquiring an additional 13,735 shares during the last quarter. BBR Partners LLC acquired a new position in Enzo Biochem during the 3rd quarter valued at about $112,000. Geode Capital Management LLC boosted its stake in Enzo Biochem by 3.3% in the third quarter. Geode Capital Management LLC now owns 368,646 shares of the medical research company’s stock valued at $413,000 after acquiring an additional 11,742 shares during the last quarter. Finally, Renaissance Technologies LLC grew its stake in shares of Enzo Biochem by 2.6% during the second quarter. Renaissance Technologies LLC now owns 2,499,546 shares of the medical research company’s stock worth $2,725,000 after purchasing an additional 64,417 shares during the period. 36.90% of the stock is currently owned by institutional investors.

Enzo Biochem Company Profile

Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.